Anti-BCMA chimeric antigen receptor T cell therapy (Cartesian)

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug NameAnti-BCMA chimeric antigen receptor T cell therapy (Cartesian)
Drug Alias NameAnti-BCMA CAR-T cell therapy - Cartesian TherapeuticsDescartes-08
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-BCMA
TargetsB-cell maturation protein
Therapy Area/IndicationsAnti-synthetase SyndromeLupus Erythematosus, SystemicAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPoland +[7] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCartesian Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCartesian Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsAnti-synthetase SyndromeLupus Erythematosus, SystemicAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[5] 
Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksN/A